Tiny biotech takes on Glaxo’s $730000 gene therapy – SFGate
|
Tiny biotech takes on Glaxo's $730000 gene therapy
SFGate GlaxoSmithKline has seen precious few takers for its $730,000 gene therapy for a rare and life-threatening immune illness known as “bubble-boy disease.” Now a tiny startup thinks it can succeed where the British giant is struggling. In almost two years … |
